Compare FINW & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FINW | IPHA |
|---|---|---|
| Founded | 1999 | 1999 |
| Country | United States | France |
| Employees | 198 | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 194.1M | 165.3M |
| IPO Year | 2021 | 2014 |
| Metric | FINW | IPHA |
|---|---|---|
| Price | $13.85 | $2.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.75 |
| AVG Volume (30 Days) | 20.2K | ★ 184.0K |
| Earning Date | 04-30-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 21.51 | N/A |
| EPS | ★ 0.35 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $160.48 | $180.36 |
| Revenue Next Year | $35.27 | N/A |
| P/E Ratio | $39.96 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.82 | $1.18 |
| 52 Week High | $22.49 | $2.71 |
| Indicator | FINW | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 46.44 | 46.64 |
| Support Level | $13.72 | $1.67 |
| Resistance Level | $14.62 | $2.29 |
| Average True Range (ATR) | 0.39 | 0.08 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 46.53 | 6.67 |
FinWise Bancorp is an independent bank that provides a full range of banking services to individual and commercial customers. The bank's primary source of revenue is from loans, including Small Business Administration, commercial, commercial real estate, residential real estate, and consumer. The Bank has also established Strategic Programs with various third-party loan origination platforms that use technology to streamline the origination of unsecured consumer and secured or unsecured business loans to borrowers within certain approved credit profiles.
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.